Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?

Bristol Myers Squibb shares have risen 42% over the past 12 months, versus a 15% gain for the S&P 500, while the stock trades at 9.4x forward earnings compared with 18.5x for healthcare peers. Q2 revenue increased 6% year over year to roughly $13 billion and non-GAAP EPS rose 40% to $2.04, but Eliquis and Opdivo—together representing more than half of revenue—face U.S. patent expirations by decade-end. The company is positioning newer products including Reblozyl, whose sales rose 29% to $735 million, Opdivo Qvantig, and pipeline programs pumitamig and milvexian to offset future generic and biosimilar pressure; its forward dividend yield is 4.0%.

Analysis

BMY's low multiple is not simply a value signal; it reflects an unusually concentrated loss-of-exclusivity exposure that makes the terminal earnings base highly uncertain. The key underwriting question is whether subcutaneous Opdivo conversion creates durable post-IV switching economics rather than merely shifting revenue between formulations before competitive entry. Conversion rates, payer coverage, and net-price realization are more informative near-term KPIs than reported franchise sales growth; weak conversion would reopen downside to consensus long-term estimates quickly.

The more consequential read-through is for PFE: Eliquis erosion is a shared economic risk, but BMY has greater incentive to establish milvexian as a successor. A successful factor XIa anticoagulant could cannibalize the legacy franchise before generics do, while failure leaves both companies exposed to price-led generic substitution. This creates a binary clinical/regulatory catalyst over the next 12-24 months, not a conventional defensive-pharma earnings setup.

After a sharp rerating, BMY is less attractive as an outright pre-catalyst value long than it was when sentiment was uniformly negative. The market may still underappreciate the cash-flow support from the dividend and cost discipline over the next 1-3 quarters, but it is likely overestimating management's ability to bridge a large late-decade revenue gap solely through early pipeline assets. The thesis is falsified positively by sustained Qvantig conversion with stable franchise net pricing and credible late-stage milvexian efficacy; it is falsified negatively by guidance cuts to 2028-30 revenue, adverse pivotal data, or accelerating Eliquis price concessions.

Key Decisions for Investors

• Maintain a market-neutral relative-value position: long BMY / short PFE in equal beta-adjusted dollars for 3-6 months. BMY has more identifiable product-conversion and operating-leverage catalysts, while PFE has less visibility on replacing Eliquis economics; exit if the relative spread tightens 12-15% or if BMY reduces medium-term revenue guidance.
• Do not chase BMY outright following the recent rerating. Add only on a 8-10% pullback or after quarterly evidence that Qvantig adoption is incremental to retention and does not require materially higher rebates; target a 10-15% total-return profile including carry over 12 months, with downside limited by a 7% stop from entry.
• Establish an event watch on BMY and BNTX around pumitamig clinical updates rather than taking directional BNTX exposure. Require independently disclosed response durability, safety, and trial-enrollment quality before assigning material revenue value; early oncology data alone is insufficient to offset BMY's patent-cliff risk.
• For income mandates, BMY can replace part of an XLP-style defensive allocation only with a defined 12-18 month review point. The dividend yield is compensation for earnings-duration risk, not a substitute for pipeline validation; reduce if payout growth exceeds underlying free-cash-flow growth or leverage rises following business-development activity.